Surveillance for isocyanate asthma: A model based cost effectiveness analysis

Occupational and Environmental Medicine

Volumn 62, Issue 11, 2005, Pages 743-749

  Wild, D M ^a,b   Redlich, C A ^b   Paltiel, A D ^b  

^a GRIFFIN HOSPITAL   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISOCYANIC ACID DERIVATIVE;

ABSENTEEISM; ARTICLE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; EMPLOYER; HEALTH SURVEY; HUMAN; MATHEMATICAL MODEL; MEDICAL DECISION MAKING; OCCUPATIONAL ASTHMA; OCCUPATIONAL EXPOSURE; OUTCOMES RESEARCH; PHYSICAL DISABILITY; PREDICTION; PRIORITY JOURNAL; PRODUCTIVITY; QUALITY ADJUSTED LIFE YEAR; QUESTIONNAIRE; RESOURCE ALLOCATION; SENSITIVITY ANALYSIS; SOCIETY; SPIROMETRY; SYMPTOM;

ABSENTEEISM; ADOLESCENT; ADULT; AGED; ASTHMA; COST OF ILLNESS; COST-BENEFIT ANALYSIS; EFFICIENCY; FEMALE; HUMANS; ISOCYANATES; MALE; MIDDLE AGED; MODELS, ECONOMETRIC; OCCUPATIONAL DISEASES; OCCUPATIONAL HEALTH SERVICES; POPULATION SURVEILLANCE; QUALITY-ADJUSTED LIFE YEARS; UNITED STATES;

EID: 27644565774     PISSN: 13510711     EISSN: None     Source Type: Journal    
DOI: 10.1136/oem.2004.016147     Document Type: Article

References (45)

1. Bernstein D. Allergic reactions to workplace allergens. JAMA 1997;278:1907-13.
2. Chan-Yeung M, Malo J-L. Natural history of occupational asthma. In: Bernstein IL, Chan-Yeung M, Malo J-L, Bernstein DI, eds. Asthma in the workplace. New York, Basel: Marcel Dekker, 1999:129-43.
3. Bernstein JA. Overview of diisocyanate occupational asthma. Toxicology 1996;111:181-9.
4. Baur X, Stahlkopf H, Merget R. Prevention of occupational asthma including medical surveillance. Am J Ind Med 1998;34:632-9.
5. Dedhia HV, Rando RJ, Banks DE. Can we protect workers from developing the adverse respiratory effects of isocyanate exposure? Occ Med 2000;15:399-410.
6. Chan-Yeung M, Lam S, Koener S. Clinical features and natural history of occupational asthma due to Western Red Cedar (Thuja Plicata). Am J Med 1982;72:411-15.
7. Pisati G, Baraffuni A, Zedda S. Toluene Diisocyanate induced asthma: Outcome according to persistence of cessation of exposure. Br Ind Med 1993;50:60-4.
8. Paggiaro PL, Vagaggini B, Bacci E. Prognosis of occupational asthma. Eur Respir J 1994;7:761-7.
9. Tarlo SM, Liss G, Corey P, et al. A workers' compensation claim population for occupational asthma: Comparison of subgroups. Chest 1995;107:634-41.
10. Tarlo SM, Banks D, Liss G, et al. Outcome determinants for Isocyanate induced occupational asthma among compensation claimants. Occup Environ Med 1997;54:756-61.
11. Perfetti L, Cartier H, Ghezzo D, et al. Follow-up of occupational asthma after removal from or diminution of exposure to the responsible agent: Relevance of the length of the interval from cessation of exposure. Chest 1998;114:398-403.
12. Ross DJ, McDonald JC. Health and employment after a diagnosis of occupational asthma: A descriptive study. Occup Med 1998;48:219-25.
13. Tarlo SM, Liss GM, Yeung KS. Changes in rates and severity of compensation claims for asthma due to Diisocyanates: A possible effect of medical surveillance measures. Occup Environ Med 2002;59:58-62.
14. Tarlo SM, Liss G. Surveillance and prevention of occupational asthma. Can J Allergy Clin Immunol 1998;3:182-5.
15. Gold MR, Siegel JE, Russel LB, et al. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996.
16. Weinstein MC, Siegel JE, Gold MR, et al. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 1996;276:1253-8.
17. Chapman RH, Stone PW, Sandberg EA, et al. A comprehensive league table of cost-utility ratios and a sub-table of "panel-worthy" studies. Med Decis Making 2000;20:451-67.
18. Sullivan SD, Elixhauser A, Buist AS, et al. National asthma education and prevention program working group report on the cost-effectiveness of asthma care. Am J Respir Crit Care Med 1996;154:584-595.
19. US Department of Labor, Bureau of Labor Statistics. Available at http://data.bls.gov/servlet (accessed 31 January 2003).
20. Diller WF. Frequency and trends of occupational asthma due to Toluene Diisocyanate: A critical review. Applied Occ Env Hygiene 2002;17:872-7.
21. Ott GM, Klees JE, Poche SL. Respiratory health surveillance in a Toluene Di-Isocyanate production unit 1967-97: Clinical observations and lung function analyses. Occ Env Med 2000;57:43-52.
22. Woellner RC, Hall X, Greaves I, et al. Epidemic of asthma in a wood products plant using Methylene Diphenyl Diisocyanate. Am J Ind Med 1997;31:56-63.
23. Petsonk EL, Wang ML, Lewis DM, et al. Asthma-like symptoms in wood product plant workers exposed to Methylene Diphenyl Diisocyanate. Chest 2002;118:1183-93.
24. Tarlo SM, Liss GM. Diisocyanate-induced asthma: Diagnosis, prognosis, and effects of medical surveillance measures. Applied Occ Envir Hygiene 2002;17:902-8.
25. Redlich CA, Karol MH. Diisocyanate asthma: Clinical aspects and immunogenesis. Intern Immunopharmacol 2002;2:213-24.
26. Finkler SA. The distinction between costs and charges. Ann Intern Med 1982;96:102-9.
27. Karson GK. 2003 Industry Profile. Available at http://www.babcox.com/ editorial/bb/personnel.pdf (accessed 31 January 2003).
28. Moscato G, Dellabianca A, Perfetti L, et al. A longitudinal study on the clinical and socioeconomic outcome after diagnosis. Chest 1999;115:249-56.
29. Birnbaum HG, Berger WE, Greenberg PE, et al. Direct and indirect costs of asthma to an employer. J Allergy Clin Immunol 2003;109:264-70.
30. Schulpher MJ, Buxton MJ. The episode-free day as a composite measure of effectiveness. PharmacoEoconomics 1993;4:345-52.
31. Johnson NL, Kotz S, Balakrishnan N. Continuous univariate distributions. New York: John Wiley & Sons, 1995.
32. Paltiel AD, Fuhlbrigge AL, Kitch BT, et al. Cost-effectiveness of inhaled corticosteroids in adults with mild-to-moderate asthma: Results from the Asthma Policy Model. J All and Clin Immunol 2001;108:39-46.
33. Salzmann P, Kerlikowske K, Phillips K. Cost-effectiveness of extending screening mammography guidelines to include women 40 to 49 years of age. Ann Int Med 1997;127:955-65.
34. Frazier AL, Colditz GA, Fuchs CS, et al. Cost-effectiveness of screening for colorectal cancer in the general population. JAMA 2000;284:1954-56.
35. CDC Diabetes Cost-Effectiveness Study Group. The cost-effectiveness of screening for type 2 diabetes. JAMA 1998;280:1757-63.
36. Milton DK, Solomon GM, Rosiello RA, et al. Risk and incidence of asthma attributable to occupational exposure among HMO members. Am J Ind Med 1998;33:1-10.
37. Arnaiz CL. New developments in work-related asthma. Clin Chest Med 2002;23:737-47.
38. Vandenplas O, Malo J-L, Saefta M, et al. Occupational asthma and extrinsic alveolitis due to isocyanates: Current status and perspectives. Brit J Ind Med 1993;50:213-28.
39. Musk AW, Peters JM, Wegman DH. Isocyanates and respiratory disease: current status. Am J Ind Med 1988;13:331-49.
40. Simpson C, Garabrant D, Torrey S, et al. Hypersensitivity pneumonitis-like reaction and occupational asthma associated with 1.3-bis-isocyantaomethyl cyclohexane pre-polymer. Am J Ind Med 1996;30:48-55.
41. Blanc PD, Trupin L, Eisner L, et al. The work impact of asthma and rhinitis: findings from a population based survey. J Clin Epi 2001;54:610-18.
42. Gannon PFG, Weir DC, Robertson ASD, et al. Consequences of occupational asthma. Respir Med 1989;83:437-40.
43. Wheeler S, Rosenstock L, Barnhart S. A case series of 71 patients referred to a hospital-based occupational and environmental medicine clinic for occupational asthma. WPM 1998;168:98-104.
44. Mapp CE, Corona PC, De Marzo N, et al. Persistent asthma due to isocyanates. A follow-up study of subjects with occupational asthma due to Toluene Diisoyanate. Am Rev Resp Dis 1988;137:1326-9.
45. Gassert TH, Hu H, Kelsey K, et al. Long-term health and employment outcomes of occupational asthma and their determinants. JOEM 1998;40:481-91.